Gates Medical Research Institute and the Serum Institute of India reach agreement for the manufacture of M72/AS01E TB vaccine candidate, pending successful Phase 3 outcomes - European AIDS Treatment Group

Gates Medical Research Institute and the Serum Institute of India reach agreement for the manufacture of M72/AS01E TB vaccine candidate, pending successful Phase 3 outcomes European AIDS Treatment GroupIndia's Serum Institute partners with Gates MRI to make experimental TB vaccine ReutersCurrent Affairs for 17 July 2026 Sanskriti IASManufacturer agreed for the M72 TB vaccine candidate | News wellcome.orgGSK-developed TB vaccine candidate progresses toward global access with new manufacturing agreement GSK